Skip to main content
. 2016 Nov 6;7(4):550–555. doi: 10.4292/wjgpt.v7.i4.550

Table 5.

Success rate and underlying disease: Secondary eradication therapy

PPI group Vonoprazan group P value
ITT analysis 91.5% (292/319) 89.6% (43/48) 0.59
Chronic gastritis
PP analysis 93.9% (292/311) 100% (43/43) 0.15
ITT analysis 86.4% (38/44) 100% (8/8) 0.57
Peptic ulcer
PP analysis 95.0% (38/40) 100% (8/8) 1
ITT analysis 78.6% (22/28) 80% (8/10) 1
After endoscopic therapy for early gastric cancer
PP analysis 78.6% (22/28) 80% (8/10) 1

PPI: Proton pump inhibitor.